These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

401 related items for PubMed ID: 24889275

  • 41. Activity of single-agent melphalan 220-300 mg/m2 with amifostine cytoprotection and autologous hematopoietic stem cell support in non-Hodgkin and Hodgkin lymphoma.
    Phillips GL, Meisenberg BR, Reece DE, Adams VR, Badros AZ, Brunner JL, Fenton RG, Filicko J, Grosso DL, Hale GA, Howard DS, Johnson VP, Kniska A, Marshall KW, Mookerjee B, Nath R, Rapoport AP, Sarkodee-Adoo C, Takebe N, Vesole DH, Wagner JL, Flomenberg N.
    Bone Marrow Transplant; 2004 Apr; 33(8):781-7. PubMed ID: 14767498
    [Abstract] [Full Text] [Related]

  • 42. Photobiomodulation: a promising innovative approach for preventing oral mucositis in patients undergoing hematopoietic stem cell transplantation.
    Stocker N, Baltes V, Bellaiche S, Brouillard F, Belmoufid N, Rousseau C, Bonnin A, Van de Wyngaert Z, Ricard L, Banet A, Malard F, Duléry R, Mohty M, Brissot E.
    Support Care Cancer; 2022 Oct; 30(10):8211-8216. PubMed ID: 35810217
    [Abstract] [Full Text] [Related]

  • 43. Effect of melphalan 140 mg/m(2) vs 200 mg/m(2) on toxicities and outcomes in multiple myeloma patients undergoing single autologous stem cell transplantation-a single center experience.
    Katragadda L, McCullough LM, Dai Y, Hsu J, Byrne M, Hiemenz J, May S, Cogle CR, Norkin M, Brown RA, Wingard JR, Chang M, Moreb JS.
    Clin Transplant; 2016 Aug; 30(8):894-900. PubMed ID: 27219740
    [Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45. [Cryotherapy is useful and safe in the prevention of oral mucositis after high-dose melphalan (L-PAM)].
    Inagaki N, Ohue Y, Shigeta H, Tasaka T.
    Rinsho Ketsueki; 2006 Nov; 47(11):1469-71. PubMed ID: 17176891
    [Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48. Induction bortezomib in Al amyloidosis followed by high dose melphalan and autologous stem cell transplantation: a single institution retrospective study.
    Scott EC, Heitner SB, Dibb W, Meyers G, Smith SD, Abar F, Kovacsovics T, Perez-Avraham G, Stentz A, Frires R, Dibb J, Maziarz RT.
    Clin Lymphoma Myeloma Leuk; 2014 Oct; 14(5):424-430.e1. PubMed ID: 24650974
    [Abstract] [Full Text] [Related]

  • 49. Feasibility of second hematopoietic stem cell transplantation using reduced-intensity conditioning with fludarabine and melphalan after a failed autologous hematopoietic stem cell transplantation.
    Hong JY, Choi MK, Kim DH, Kim SJ, Kim K, Kim WS, Chung CW, Kim HO, Min YH, Jang JH.
    Transplant Proc; 2010 Nov; 42(9):3723-8. PubMed ID: 21094846
    [Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51. Busulfan plus melphalan versus high-dose melphalan as a conditioning regimen for autologous stem cell transplantation in multiple myeloma with high-risk features (KMM 2015).
    Kim M, Lee JJ, Min CK, Lee JY, Jo JC, Yoon SS, Lim SN, Do YR, Kim K, Lee JH, Yoo KH, Bae SH, Yi JH, Jung J, Eom HS, Jung SH.
    Ann Hematol; 2023 Aug; 102(8):2233-2240. PubMed ID: 37392367
    [Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53. Effects of cryotherapy on high-dose melphalan-induced oral mucositis in pediatric patients undergoing autologous stem cell transplantation.
    Kawaguchi K, Umeda K, Takachi T, Ogura T, Horikoshi Y, Saida S, Kato I, Hiramatsu H, Adachi S, Takita J, Watanabe K.
    Pediatr Blood Cancer; 2020 Sep; 67(9):e28495. PubMed ID: 32573946
    [Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55. Results of a retrospective single institution analysis of targeted skeletal radiotherapy with (166)Holmium-DOTMP as conditioning regimen for autologous stem cell transplant for patients with multiple myeloma. Impact on transplant outcomes.
    Christoforidou AV, Saliba RM, Williams P, Qazilbash M, Roden L, Aleman A, Weber D, Mendoza F, Podoloff D, Wendt R, Breitz H, Alexanian R, Champlin R, Giralt S.
    Biol Blood Marrow Transplant; 2007 May; 13(5):543-9. PubMed ID: 17448913
    [Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 58. Variability of high-dose melphalan exposure on oral mucositis in patients undergoing prophylactic low-level laser therapy.
    Rodrigues GH, Jaguar GC, Alves FA, Guollo A, Camandoni VO, Damascena AS, Lima VCC.
    Lasers Med Sci; 2017 Jul; 32(5):1089-1095. PubMed ID: 28512727
    [Abstract] [Full Text] [Related]

  • 59. Cryotherapy reduces oral mucositis and febrile episodes in myeloma patients treated with high-dose melphalan and autologous stem cell transplant: a prospective, randomized study.
    Marchesi F, Tendas A, Giannarelli D, Viggiani C, Gumenyuk S, Renzi D, Franceschini L, Caffarella G, Rizzo M, Palombi F, Pisani F, Romano A, Spadea A, Papa E, Canfora M, Pignatelli A, Cantonetti M, Arcese W, Mengarelli A.
    Bone Marrow Transplant; 2017 Jan; 52(1):154-156. PubMed ID: 27526285
    [No Abstract] [Full Text] [Related]

  • 60. Pharmacoeconomic analysis of palifermin to prevent mucositis among patients undergoing autologous hematopoietic stem cell transplantation.
    Nooka AK, Johnson HR, Kaufman JL, Flowers CR, Langston A, Steuer C, Graiser M, Ali Z, Shah NN, Rangaraju S, Nickleach D, Gao J, Lonial S, Waller EK.
    Biol Blood Marrow Transplant; 2014 Jun; 20(6):852-857. PubMed ID: 24607557
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 21.